PHOTO : AFP
India's lucrative generic drug sector received a hard blow when the US accused it of 'diluting' the medicine with filler compounds.
On Monday, the company responsible for the wrongdoing responded that the finding was a spurious attempt at ruining the Indian pharmaceutical sector on the part of competitors worldwide.
The company also asserts that its pharmaceutical production is withing the context and scope of one of the strictest and best regulated industrial sectors in the country.
However, the drug firm accused to tampering with the generic pharmaceutical product, has already pled guilty to the charges.
Ranbaxy Laboratories, India's largest producer of generics, was the company accused of tampering with the generic compounds, and has agreed to a settlement penalty of 500 million US dollars. Some of the generics produced here had as little as 10% of the active component of the compound in it.
Furthermore, the investigation that found the corrupted generics was initiated by an employee of Ranbaxy and not from prior testing of the generics by the FDA.
The safety of Indian made generics is now in question. Especially since some of the medication generics they produced was for Tb and Aids patients, who then suffered grave consequences for what were medications with only a small percentage of the active principle in them.
The firm, Ranbaxy. had been acquired by Japan in 2008, although the Japanese authorities have since determined that the prior owners and principals of the company hid vital information about US regulatory investigations at the time of the acquisition.
Source : France 24/ 6.3.13
No comments:
Post a Comment